Amanzhan Abubakirov

Statistics

Publications

Citations

112

H-Index

Active since

2024

Affiliations

Université de Montpellier(Current)

Inserm

Laboratoire National de Référence

University College London

EsSALUD

Amanzhan Abubakirov is an author at Université de Montpellier specializing in drug-susceptible tuberculosis treatment, response-adaptive randomization, and tuberculosis care.

ORCID

Publications per year

2024–2025

Publications

Oral Regimens for Rifampin-Resistant, Fluoroquinolone-Susceptible Tuberculosis

Lorenzo Guglielmetti, Uzma Khan, Gustavo E. Velásquez et al. · New England Journal of Medicine · 2025 · 76 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +16

Bedaquiline, delamanid, linezolid, and clofazimine for rifampicin-resistant and fluoroquinolone-resistant tuberculosis (endTB-Q): an open-label, multicentre, stratified, non-inferiority, randomised, controlled, phase 3 trial

Lorenzo Guglielmetti, Uzma Khan, Gustavo E. Velásquez et al. · The Lancet Respiratory Medicine · 2025 · 24 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +14

Nine-month, all-oral regimens for rifampin-resistant tuberculosis

Lorenzo Guglielmetti, Uzma Khan, Gustavo E. Velásquez et al. · medRxiv · 2024 · 12 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +15

1–3 of 3